Liminatus Pharma, Inc. (NASDAQ: LIMN) has a pending merger agreement that, if approved by stockholders, would issue 1,600,000,000 new shares of common stock — roughly 55 times the company's current public float of approximately 28.9 million shares. The deal, announced May 20, 2026, would acquire InnocsAI LLC in what amounts to a reverse merger with an outside closing date of December 31, 2026.

The CEO is on both sides of the transaction. Chris Kim controls Valetudo Therapeutics LLC, which is a member of InnocsAI — meaning the individual running the acquirer also holds an interest in the target. The merger consideration includes a contingent value right — a contractual claim entitling InnocsAI members to 20 percent of net proceeds from any future sale or out-license of InnocsAI assets.

That merger alone would redefine the company. But the existing structure is already strained.

Current Overhang

LIMN carries 26.95 million shares in near-the-money or in-the-money warrants — equivalent to 93 percent of today's 28.9 million adjusted float. The largest block is 20.7 million common warrants exercisable at $0.29, issued in a February 2026 best-efforts public offering — a type of deal in which the underwriter makes no guarantee that the full amount will be sold. Another 5.5 million pre-funded warrants sit at a $0.0001 strike, meaning they are economically identical to common stock and can be exercised at any time for essentially nothing.

Both tranches are registered for immediate resale under an S-1 that became effective February 13, 2026, covering 35.2 million shares in total.

Sponsor and Insider Supply

Iris Acquisition Holdings LLC, the SPAC sponsor from LIMN's April 2025 de-SPAC, holds 6.9 million founder shares acquired at $0.004 each. Those shares were registered for resale — meaning they were filed with the SEC so they could be freely sold in the open market — via a prospectus supplement effective August 2025. They are now free-trading.

Separately, a web of related-party convertible loans from entities including Valetudo, Prophase, Hana, Ewon, Amantes, and CarT-cellkor remains on the books. Conversion terms have not been disclosed in available filings, creating an unquantified layer of potential share issuance controlled by insiders.

Financing Cadence

Since April 2025, the company has executed five capital-structure events in 13 months: the de-SPAC closing with a $15 million PIPE — a private investment in public equity — priced at $10.00 per share, a resale registration of 20.5 million shares, a best-efforts offering netting $3.46 million, and now the InnocsAI merger announcement. The February 2026 offering agreement includes a 180-day standstill — a contractual prohibition on additional share issuances or variable-rate transactions — but that restriction does not appear to apply to the merger consideration shares. It expires around August 17, 2026.

Dilution Risk Grade: 9 out of 10 (Extreme)

The score reflects the combination of a pending mega-issuance controlled by a related party, a near-the-money warrant overhang exceeding 90 percent of the current float, undisclosed convertible loan terms, and a serial financing pattern that has grown shares outstanding by roughly 157 percent in the trailing twelve months — from a weighted average of 17.5 million diluted shares in fiscal 2024 to 44.9 million outstanding today.

If the InnocsAI merger closes as proposed, total potential shares that could enter the float within twelve months reach approximately 1.63 billion — roughly 56 times the current adjusted float of 28.9 million.